- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06802796
Plasma NGAL in APN Patients
January 25, 2025 updated by: Elsayed Abdelhalim Elsayed, Kafrelsheikh University
Plasma NGAL as a Predictor to Acute Pyelonephritis : Case -Control Cohort Study .
In recent years, novel biomarkers of renal dysfunction have attracted attention for the diagnosis of UTIs.
NGAL is a 25 kDa protein that belongs to the lipocalin.
It acts as a transporter for small hydrophobic molecules and is involved in many physiological processes, such as modulating inflammation, innate immune response, and maintaining metabolic homeostasis
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
120
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Zagazig, Egypt, 44749
- Elsayed Abdelhalim Elsayed
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
All adult patient had fever due to renal infection
Description
Inclusion Criteria:
- above 20 years Suspected have pyelonphirtis
Exclusion Criteria:
- age below 20
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Group A :patient with pyelonephritis
patient with pyelonephritis
|
Human neutrophil gelatinase-associated lipocalin ELISA Kit from BT LAB® Bioassay technology laboratory was used for the estimation of serum NGAL.
Procedure was done according to the manufacturer's instructions.
|
|
Group B :patient without pyelonephritis
patient without pyelonephritis
|
Human neutrophil gelatinase-associated lipocalin ELISA Kit from BT LAB® Bioassay technology laboratory was used for the estimation of serum NGAL.
Procedure was done according to the manufacturer's instructions.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Result of plasma NGAL test
Time Frame: One day
|
Result of serum test of NGAL
|
One day
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 1, 2024
Primary Completion (Actual)
June 1, 2024
Study Completion (Actual)
June 1, 2024
Study Registration Dates
First Submitted
January 25, 2025
First Submitted That Met QC Criteria
January 25, 2025
First Posted (Actual)
March 25, 2025
Study Record Updates
Last Update Posted (Actual)
March 25, 2025
Last Update Submitted That Met QC Criteria
January 25, 2025
Last Verified
January 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KFSIRB200-143
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pyelonephritis
-
Hospital Universitario Dr. Jose E. GonzalezUnknownEmphysematous PyelonephritisMexico
-
Paratek Pharmaceuticals IncCompletedAcute PyelonephritisGeorgia, Latvia, Russian Federation, Ukraine
-
University Hospital, Clermont-FerrandCompletedAcute Uncomplicated PyelonephritisFrance
-
University of Southern DenmarkCompletedAcute PyelonephritisDenmark
-
University of Southern DenmarkCompletedAcute PyelonephritisDenmark
-
Shahid Beheshti UniversityUnknownAcute Pyelonephritis(APN)Iran, Islamic Republic of
-
University of ManitobaJanssen-Ortho Inc., Canada; PriCara, Unit of Ortho-McNeil, Inc.; Ortho-McNeil...TerminatedAcute Uncomplicated PyelonephritisCanada
-
Shahid Beheshti UniversityUnknownAcute Pyelonephritis(APN)Iran, Islamic Republic of
-
MerLion Pharmaceuticals GmbHCompletedUrinary Tract Infections | Acute PyelonephritisGermany
-
University of Southern DenmarkCompleted
Clinical Trials on Plasma NGAL test
-
Centre Hospitalier Universitaire de NīmesCompletedAcute Kidney Failure | RhabdomyolysisFrance
-
BioPorto DiagnosticsUnknownKidney InjuryUnited States
-
Kasr El Aini HospitalCompletedAnemia | Acute Kidney InjuryEgypt
-
Sohag UniversityCompletedTo Determine If Blood Level (NGAL) Could Accurately Early Detect Acute Renal Damage in All Patients Requiring Critical CareEgypt
-
Assiut UniversityNot yet recruitingMultiple Myeloma(MM)
-
Uijeongbu St. Mary HospitalTerminatedOut-of-Hospital Cardiac ArrestKorea, Republic of
-
The AlfredBiositeCompleted
-
Fondation LenvalCompleted
-
BioPorto DiagnosticsProPharma GroupActive, not recruitingAcute Kidney InjuryUnited States